跳至主要内容
临床试验/NCT01349699
NCT01349699已完成不适用

Effects of Iron Loading and Iron Chelation Therapy on Innate Immunity During Human Endotoxemia

Radboud University Medical Center0 个研究点目标入组 30 人开始时间: 2010年2月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
30
主要终点
TNF-alfa

研究概览

简要总结

Iron affects immunity. However, the exact effect of iron on the innate immune response is not known. Animal data suggest that iron administration induced oxidative stress which enhances the innate immune response, whereas iron chelation has the opposite effect. The investigators tested the hypothesis that administration of iron sucrose 1.25 mg/kg augments the innate immune response, and iron chelation by deferasirox 30 mg/kg attenuates the innate immune response during human experimental endotoxemia.

详细描述

Systemic inflammation is accompanied by profound changes in iron distribution, mainly under the influence of hepcidin, leading to sequestration of iron in macrophages of the reticuloendothelial system, and ultimately anemia of inflammation. This redistribution of iron may represent an effective defense mechanism against a variety of pathogens, that need iron for replication and growth. The fact that iron withholding strategy is such a highly conserved part of the innate immune response illustrates that iron homeostasis and immunity are closely related. Concordantly, several studies in animal models have revealed immune modulatory effects of both iron and iron chelation: Iron sucrose has been shown to potentiate the inflammatory response and associated mortality, while iron chelation appears to attenuate inflammation and improve outcome in murine models of inflammation and sepsis. The immune modulatory effects of iron supplements and chelators are mainly attributed to their ability to potentiate or reduce the formation of reactive oxygen species (ROS). A subfraction of non-transferrin bound catalytically active iron, labile plasma iron, is thought to be responsible as this free iron is able to easily donate or accept electrons, thereby fueling redox reactions. Oxidative stress is associated with propagation of the immune response, endothelial dysfunction, and contributes to the organ damage that occurs during systemic inflammation. In accordance, anti-oxidants exert anti-inflammatory effects. As such, iron chelation has been suggested to be a valuable adjuvant therapy during infection for two distinct reasons: inhibition of bacterial growth and protection of organs against inflammation induced oxidative stress.

Effects of iron status on the immune response has up till now mainly been investigated in in vitro and in animal models, often using supra-therapeutic dosages of iron donors or iron chelators. Data on the effect of iron loading and iron chelation during systemic inflammation in humans are lacking. The objectives of the present study were to investigate the acute effect of therapeutic dosages of iron loading and iron chelation therapy on iron homeostasis, oxidative stress, the innate immune response, and subclinical organ injury during systemic inflammation induced by experimental endotoxemia in humans in vivo.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Triple (Participant, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 35 Years(Adult)
性别
Male
接受健康志愿者

入选标准

  • between 18 and 35 years of age

排除标准

  • use of prescription drugs
  • febrile illness < 2 weeks before the study date
  • abnormalities found at screening
  • participation in another trial in the preceding 6 months
  • iron disorders in the family

研究组 & 干预措施

Iron loading

Active Comparator

Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.

干预措施: iron sucrose (Drug)

Iron loading

Active Comparator

Subjects will receive 1.25 mg/kg iron sucrose intravenously 1 hour before endoxin administration 2ng/kg.

干预措施: endotoxin (Drug)

Iron chelation

Active Comparator

Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.

干预措施: Deferasirox (Drug)

Iron chelation

Active Comparator

Subjects will receive 30mg/kg deferasirox orally 2 hours before endotoxin administration 2ng/kg.

干预措施: endotoxin (Drug)

Placebo

Placebo Comparator

Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration

干预措施: endotoxin (Drug)

Placebo

Placebo Comparator

Subjects will receive placebo instead of iron chelation or iron loading before endotoxin administration

干预措施: Placebo (Drug)

结局指标

主要结局

TNF-alfa

时间窗: Level of TNF-alfa 90 minutes after endotoxin administration

Level of TNF-alfa 90 minutes after endotoxin administration

次要结局

  • Cytokines(24 hrs after the administration of endotoxin)
  • Oxidative stress(24 hrs after the administration of iron / iron chelator / placebo)
  • Hemodynamic response(24 hours after the administration of endotoxin)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Peter Pickkers

MD. PhD

Radboud University Medical Center

相似试验

Effects of Iron Loading and Iron Chelation Therapy... | 临床试验